Letters to the Editor

Effectiveness of Glucosamine and Chondroitin for Osteoarthritis

Am Fam Physician. 2012 Dec 1;86(11):994-998.

Original Article: Osteoarthritis: Diagnosis and Treatment

Issue Date: January 1, 2012

Available at: http://www.aafp.org/afp/2012/0101/p49.html

TO THE EDITOR: This article repeated a common misconception about the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), interpreting it as showing that the combination of glucosamine and chondroitin is effective for treating moderate to severe osteoarthritis.1 The study found that glucosamine and chondroitin, separately or in combination, were not more effective than placebo. Only one of 10 subgroups showed statistically significant results, and these were for moderate to severe arthritis. With 10 subgroups, it is likely that chance alone would produce false-positive results in one of these groups. The authors of the study warned that it was not powered to differentiate among subgroups, and that no clinical recommendations should be made based on that finding.1

The AFP article recommends a combination of glucosamine and chondroitin as the third step in a stepped-care approach for the treatment of osteoarthritis. This is not justified by the evidence. In addition, the rationale is suspect because glucosamine and chondroitin are produced by the body. The amount added by taking supplements is only a minuscule fraction of what is already present. These are not essential nutrients like vitamins, of which taking a small amount is likely to make a large difference.

Author disclosure: No relevant financial affiliations to disclose.

REFERENCE

1. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795–808.

IN REPLY: I appreciate Dr. Hall's thoughtful comments. She is correct that the GAIT trial did not demonstrate a beneficial effect of glucosamine combined with chondroitin in most patients with osteoarthritis of the knee. However, there was a statistically significant benefit in the subgroup of patients with moderate to severe osteoarthritis. Of the 1,583 patients in the trial, 354 (22 percent) fell into this subgroup.1

I find that forest plots are useful in helping me visualize the effectiveness of various treatments.2 There is a set of forest plots in Figure 2 of the GAIT trial article.1 The figure shows that the combination of glucosamine and chondroitin was more effective than placebo for moderate to severe osteoarthritis based on two scoring systems: the Western Ontario and McMaster Universities Osteoarthritis Index, and the Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International. These are well-accepted clinical measures, and the differences reached statistical significance in each case.1

Dr. Hall states that “with 10 subgroups, it is likely that chance alone would produce false-positive results.” However, if statistical significance is defined as a P value of .05 or less, that corresponds to a rate of one in 20 being false-positive by chance alone, not one in 10.

Additional studies are needed to confirm the effectiveness of glucosamine and chondroitin for the treatment of osteoarthritis. For now, I stand by the recommendation for a brief trial of combined glucosamine and chondroitin in patients who have progressed to moderate or severe osteoarthritis, although the stepped-care approach in my article should state that this is only for osteoarthritis of the knee, per the evidence in the GAIT trial.

Author disclosure: No relevant financial affiliations to disclose.

REFERENCES

1. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795–808.

2. Yeh J, D'Amico F. Forest plots: data summaries at a glance. J Fam Pract. 2004;53(12):1007.

Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.

Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.


Copyright © 2012 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article